Efficacy of low molecular weight heparin for chronic obstructive pulmonary disease and respiratory failure : A protocol of systematic review of randomized controlled trials

Abstract

Background:

Evaluating the efficacy and safety of low molecular weight heparin (LMWH) for patients with chronic obstructive pulmonary disease (COPD) and respiratory failure (RF) is a major purpose of this study.

Methods:

The following electronic databases will be comprehensively retrieved from the inception to July 1, 2019: Cochrane Library, PUBMED, EMBASE, Google Scholar, Web of Science, Allied and Complementary Medicine Database, WANGFANG, and China National Knowledge Infrastructure without language restrictions. All randomized controlled trials related to LMWH for COPD and RF will be included. Two authors will carry out study selection, data collection, and risk of bias assessment independently.

Results:

This study will systematically explore the efficacy and safety of LMWH for COPD and RF. The primary outcome is lung function. The secondary outcomes are severity of dyspnea on exertion, quality of life, body mass index, airflow obstruction; and any expected and unexpected adverse events.

Conclusion:

The findings of this study will provide evidence to judge whether LMWH is an effective treatment for patients with COPD and RF.

PROSPERO registration number:

PROSPERO CRD42019 139631.